Stay updated on Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial
Sign up to get notified when there's something new on the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page.

Latest updates to the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page
- Check5 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.8.0 to v3.8.1.SummaryDifference0.0%

- Check12 days agoChange DetectedThe NCT02873962 record is now accessible, with details on the ovarian cancer study’s treatment arms, eligibility criteria, locations, and outcome measures. The record also includes posted results and a study protocol document.SummaryDifference68%

- Check19 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0 while the page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check26 days agoChange DetectedThe clinical trial record is no longer displayed; the page now shows a 403 Forbidden error with a Home link.SummaryDifference21%

- Check33 days agoChange DetectedA sitewide notice about NIH’s terminology transition appears above the page, and the site revision advances from v3.7.1 to v3.7.2. The study record area still shows a 403 error.SummaryDifference1%

- Check47 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.0 to v3.7.1 on the 403 Forbidden page.SummaryDifference0.2%

Stay in the know with updates to Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Study of Nivolumab/Bevacizumab/Rucaparib Clinical Trial page.